Specialty Pharmacy Times: 2019 Asembia Recap

From the Chairman
A Time of Change Across Specialty Pharmacy
Throughout the meeting rooms and educational sessions at the Asembia Specialty Pharmacy Summit 2019, there were clear signs that massive change could alter the industry before next year’s meeting.
Looking Back at Another Blockbuster Asembia Meeting
The annual Asembia Specialty Pharmacy Summit has become the largest meeting in the specialty space, and this year it exceeded prior numbers in attendance and offerings in programing.
Reimagining Specialty Pharmacy: Market Variability Drives New Strategies
A common theme during this year’s summit was the uncertainty about the profitability of the existing specialty pharmaceutical model.
Health Systems’ Role in Specialty Pharmacy Moves Into Focus at Asembia
Cohesion among key stakeholders, which will lead to an evolution in care, is clearly on the rise, and the growth of those relationships will only benefit patients in the end.
Massive Change Could Be Looming for Specialty Pharmacy
With drug pricing increasingly becoming a hot button issue and greater consternation surrounding the cost of treating a chronic disease among the general public, it is clear that the health care industry is at a crossroads.
Co-pay Accumulator Programs: The Debate Continues
Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers (PBMs), and manufacturers to reduce drug spend.
Oncology Innovation Fuels Rapid Pipeline Growth
The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovations in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.
How to Leverage New Technologies to Better Serve Patients
Digital innovations are opening up a world in which patients can remain better informed about their health and pharmacists can use digital metrics to help their patients make more informed health care decisions.
Specialty Lite Model Goes Beyond Improving Adherence
The "specialty-lite" platform leverages the current infrastructure of specialty pharmacies with efficient services and emerging technological solutions that focus on ensuring prescription fulfillment with economic feasibility.
CE Highlights
Diabetic Eye Conditions Contribute to Psychosocial, Financial, and Adherence Challenges
Diabetic eye disease, which includes diabetic retinopathy and macular edema, is on specialty pharmacy’s radar, especially because diabetic retinopathy alone increased 89% between 2000 and 2010.
ALS Knowledge Base Expands Treatment Options, Improves Care
Characterized by progressive focal muscle weakness that terminates with respiratory muscle failure, amyotrophic lateral sclerosis (ALS) reduces life expectancy by 3 to 5 years.
Peanut Allergy: Hope on the Horizon
Peanut allergy is not an issue only within the health care community—it is a hot topic of discussion and often discord among parents, teachers, legislators, and media commentators.
Personalizing Care in von Willebrand Disease Is Essential
Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (vWD) have been among the most common conditions addressed in these practice locations.
Changing Landscape in Chronic Lymphocytic Leukemia Demands Specialty Pharmacy’s Attention
Chronic lymphocytic leukemia is the most common leukemia in Western nations, and investigators have made great strides in clarifying the epidemiology, pathophysiology, and diagnostic criteria.
CTEPH Requires Careful, Targeted Counseling
Although rare, chronic thromboembolic pulmonary arterial hypertension (CTEPH) is of growing interest to specialty pharmacists.
Inflammatory Bowel Disease Requires Patient-Health Care Team Partnerships
Treatment for inflammatory bowel disease (IBD) has the best outcomes when patients partner with their medical teams.
hATTR: An Ultra-rare Disease Requiring Aggressive Early Intervention
Most American have never heard of hereditary transthyretin amyloidosis (hATTR), which speaks to its very low incidence rate in the population.
Idiopathic Pulmonary Fibrosis: A Specialty "Specialty"
Patients treated for idiopathic pulmonary fibrosis (IPF) respond well to the high-touch specialty pharmaceutical service model.
Therapeutic Progress Continues for Patients With Hereditary Angioedema
Diagnostic delay is a tragedy for many patients, as it increases the burden of disease and extends time to symptomatic relief or an actual cure.
Pharmacist Education Is Key to Helping Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) starts insidiously and presents as either a slowly progressive disease or a relapsing one, with partial or complete recovery between recurrences.
Clinical Pearls Help Specialty Pharmacists Improve Pulmonary Arterial Hypertension Outcomes
Still a mystery in terms of cause and cure, pulmonary arterial hypertension (PAH) is a rare and progressive disease, but, fortunately, treatments for the condition have improved.
PCSK9 Inhibitors Show Promise in Effectively Managing Hypercholesterolemia, Improving Patient Outcomes
For patients at risk for cardiovascular disease who have a less-than-expected response to statins or are intolerant of them, proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease inhibitors fill an important treatment gap.
Data: Helping Define Value-Based Care
Health system specialty pharmacies (HSSPs) are uniquely positioned to provide valuable data and superior care to the patients they serve.
Early Interventions Are Vital for Treating Influenza, Especially in Patients With Chronic Conditions
After a flu season that the CDC called one of the deadliest in recent memory, any information that can help clinicians avert patient morbidity and mortality is welcome.
Continued Development of PARP Inhibitors Improves Outcomes for Patients With Ovarian Cancer
For many years, a diagnosis of ovarian cancer—90% of which involve epithelial ovarian neoplasms—was a death sentence
New Frontiers for Pharmacists: Administration of Long-Acting Injectable Antipsychotics
Pharmacists have growing opportunities to help people living with schizophrenia and bipolar disorder.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.